TALPROXAD Trademark

Trademark Overview


On Friday, May 19, 2017, a trademark application was filed for TALPROXAD with the United States Patent and Trademark Office. The USPTO has given the TALPROXAD trademark a serial number of 87457055. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, July 5, 2024. This trademark is owned by Glaxo Group Limited. The TALPROXAD trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
talproxad

General Information


Serial Number87457055
Word MarkTALPROXAD
Filing DateFriday, May 19, 2017
Status710 - CANCELLED - SECTION 8
Status DateFriday, July 5, 2024
Registration Number5359563
Registration DateTuesday, December 19, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 3, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, July 5, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB

Trademark Events


Event DateEvent Description
Wednesday, August 16, 2017ASSIGNED TO EXAMINER
Tuesday, May 23, 2017NEW APPLICATION ENTERED
Thursday, May 25, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 13, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 3, 2017PUBLISHED FOR OPPOSITION
Tuesday, December 19, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, November 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, August 21, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 3, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, December 19, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, July 5, 2024CANCELLED SEC. 8 (6-YR)